Project Grant R01AR083365
Award Date
9/3/24
Completion Date
6/30/29
Dollars Obligated
$658K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $774,930.00 to the Regents of the University of Minnesota to develop and validate a mouse model of intervertebral disc degeneration-induced low back pain. The goal is to create a clinically representative preclinical model that can facilitate the discovery of novel non-addictive analgesics for the treatment of discogenic low...
This $366,975 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Federal Grant Program for Drug Use and Addiction Research Programs (CFDA 93.279), is funding a study to validate a rat model of chronic discogenic low back pain. The goal is to reproduce and externally validate a recently published rat model of disc degeneration-induced chronic low back pain, which could improve understanding of the underlying mechanisms and lead to better pain...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $605,253 to The Trustees of the University of Pennsylvania to investigate the mechanical crosstalk between the intervertebral disc and adjacent facet joints during spinal degeneration and repair. The research aims to characterize the progression of facet osteoarthritis following disc...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $752,620 to The Washington University to develop injectable, cell-adhesive alginate hydrogels containing insulin-like growth factor 1 (IGF-1) mimicking peptides. The goal is to enhance the therapeutic potential of mesenchymal stem cells (MSCs) for repairing degenerative intervertebral...
This $5,037,022 project grant from the National Institutes of Health's National Institute of Neurological Disorders and Stroke will support the development of novel single-cell technologies called "Raman2omics" to map pain-associated genes and cells across the lifespan. Funded under the Drug Abuse and Addiction Research Programs, the grant to the Massachusetts General Hospital aims to apply Raman2omics to systematically investigate genes and cells associated with postoperative pain...
The U.S. National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,643,228 Cooperative Agreement grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to Worcester Polytechnic Institute (WPI) to develop an Integrative Mindfulness-Based Predictive Approach for Chronic Low Back Pain Treatment (IMPACT). The key objectives of this 2-year IMPACT project are to: 1) Initiate a clinical trial of Mindfulness-Based Stress Reduction (MBSR) for chronic low back pain...
This Project Grant award of $623,628 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research into the epigenetic control of human osteogenesis mediated by long non-coding RNAs (lncRNAs). The research aims to mechanistically characterize how specific lncRNAs regulate chromatin organization and gene expression to initiate and sustain osteoblast differentiation...
This $118,457 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to elucidate the genetic underpinnings of chronic pain and identify novel non-addictive analgesic medications. The principal investigator, Dr. Sylvanus Toikumo, will leverage findings from a large multi-ancestry genome-wide association study to characterize the genetic architecture of chronic pain and pain-addiction comorbidity. The...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to investigate spinal projection neurons and their role in chronic pain. The $453,104 award, with a period of performance from February 1, 2025 to November 30, 2029, will be used by the University of Texas Southwestern Medical Center to explore the functional...
This $2,249,392 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to validate senescent cells as a target for the treatment of chronic pain in aging. The project aims to rigorously characterize the role of senescent neurons and their senescence-associated secretory phenotype (SASP) in driving dorsal root ganglion hyperexcitability and persistent pain following...